Iteos Home

Press Releases

Home / Investors / iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August

Press Release Details

iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August

August 6, 2018
PDF Version

Gosselies, Belgium – August 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that management will participate in two upcoming U.S. conferences in August. 

 

  • Managementwill be available for one-on-one meetings at the Oppenheimer Newport Summit for Revolutionary Biotechnology, on Monday, August 13, 2018 in Newport, Rhode Island.
  • Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present a company overview at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 1:20 p.m. ET in New York, NY.  

 

About iTeos Therapeutics 

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com.

 

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics

info@iteostherapeutics.com

 

Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com

 

Sarah McCabe and Carl Mauch

Stern Investor Relations, Inc.

+ 1 212 362 1200

iTeos@sternir.com

For investors

scientist picking up a petri dish

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.